Shennon Biotechnologies Raises $12 Million, Names Cyril Konto As CEO, And Unveils Precision Immunotherapy Pipeline
By Amit Chowdhry ● Sep 14, 2026
Shennon Biotechnologies has raised $12 million in new financing to advance its precision immunotherapy platform and emerging oncology pipeline while appointing biotechnology industry veteran Cyril Konto, M.D., as Chief Executive Officer. This financing was backed by Future Ventures, NextGen Venture Partners, Samos Investments, Atypical Ventures and Saras Capital, with continued participation from existing investors DCVC, Foundation Capital and AV8 Ventures. And the round brings ShennonBio's total capital raised to $25 million.